===================
Rogi1 and Rogi2 LPs
===================

We currently have monoclones for v2 and v3. The table below highlights the key attributes of each LP architecture:


V2 Rogi1/Rogi2 dual LP RMCE line:

=========       ===============      =============      ===============================              ===============================
locus            pHA for cargo        recombinase       positive selection (gene, drug)              counterselection (gene, drug)

=========       ===============      =============      ===============================              ===============================
Rogi1 LP            pKG01862                Cre                       N/A                                     iCasp9, AP1903
Rogi2 LP            pKG02278                Bxb1                      N/A                                HSV-TK SR39h, GCV or PCV
=========       ===============      =============      ===============================              ===============================

V3 Rogi1/Rogi2 dual LP single site integrase line:

=========       ===============      =============      ===============================              ===============================
locus            pHA for cargo        recombinase       positive selection (gene, drug)              counterselection (gene, drug)

=========       ===============      =============      ===============================              ===============================
Rogi1 LP            pKG02180              Bxb1                  BsdR, Blasticidin                       HSV-TK SR39h, GCV or PCV
Rogi2 LP            pKG02181             PhiC31                 BleoR, Zeocin                                iCasp9, AP1903
=========       ===============      =============      ===============================              ===============================


RMCE integration of payloads into V2 line

.. note::
   

    These protocols are still in development! Important variables that need optimization include:
    1) the ratio of recombinase to donor plasmid
    2) dosing schedule of drug selection/counterselection 
    3) scale needed to obtain a sufficient number of recombined cells 


Day -1
~~~~~~



 
